Quick to administer.
Quick to vomit.

Clevor is the first and only FDA-approved product for emesis induction in dogs.

Its selective active ingredient and unique ocular administration make the process easy and injection-free — all of which add up to a quicker, less stressful process for you, your staff, the dog, and their owner.

Labrador with chocolate bar

Fast onset of action1

Selective active ingredient

Unique ocular administration

No Financial Risk to Try

Vetoquinol Satisfaction Guarantee

Clevor is backed by Vetoquinol’s Satisfaction Guarantee

CLEVOR® is indicated for the induction of vomiting in dogs.

IMPORTANT SAFETY INFORMATION: Do not use in dogs with central nervous system depression or seizures. Do not use in cases of ingestion of sharp foreign objects, corrosive agents (acids or alkalis), volatile substances or organic solvents. CLEVOR® should not be administered in cases with corneal ulceration, ocular irritation, or ocular injury. Do not use when there is a known sensitivity to ropinirole or the inactive ingredients. ADVERSE REACTIONS MAY INCLUDE: Transient mild or moderate hyperemia of the eye, ocular discharge, protrusion of the 3rd eyelid and blepharospasm, transient mild lethargy and increased heart rate. Not recommended for use in breeding, pregnant or lactating dogs. CLEVOR® has not been evaluated in dogs with heart or liver impairments or dogs younger than 4.5 months or less than 4 pounds. Dopamine antagonists, neuroleptics and other medicines with antiemetic properties may reduce the effectiveness of ropinirole. CLEVOR® should be administered by a veterinary professional. Gloves and protective eyewear should be worn when administering. Not for use in humans. Keep out of reach of children. For full prescribing information, visit www.vetoquinolusa.com/clevor-info.


  1. Suokko, M., Saloranta, L., Lamminen, T., Laine, T., Elliott, J. (2020) Ropinirole eye drops induce vomiting effectively in dogs: a randomised, double-blind, placebo-controlled clinical study. Veterinary Record, Mar 7;186(9):283.